What Sanofi reported holding on Form 13F for the quarter ended Jun 30, 2026.
CIK 1121404 · Filed Jul 28, 2026
Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR
| 1.2M |
| ±0% |
| $109.7M |
| 20.5% |
NVAXNovavax Inc | 6.9M | ±0% | $64.8M | 12.1% |
ANABAnaptysbio, Inc | 821.9K | ±0% | $55.5M | 10.4% |
ODTXOdyssey Therapeutics, Inc. | 2M | New | $37.3M | 7% |
AGMBAgomAb Therapeutics NV | 2.8M | ±0% | $36.1M | 6.8% |
MPLTMapLight Therapeutics, Inc. | 912K | ±0% | $32.7M | 6.1% |
TRAXFirst Tracks Biotherapeutics, Inc. | 821.9K | New | $16.5M | 3.1% |
IMRXImmuneering Corp | 2.7M | ±0% | $13.5M | 2.5% |
QTTBQ32 Bio Inc. | 244.1K | ±0% | $3.1M | 0.6% |